NAS:RVNC (USA) Also trade in: Germany

Revance Therapeutics Inc

$ 11.93 0 (0%)
Volume: 249,456 Avg Vol (1m): 342,329
Market Cap $: 525.00 Mil Enterprise Value $: 254.01 Mil
P/E (TTM): 0.00 P/B: 2.24
Earnings Power Value -61.23
Net Current Asset Value 4.18
Tangible Book 5.32
Projected FCF -13.05
Median P/S Value 156
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
75.60% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
RVNC: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 10000, Max: 10000
Current: 10000
0.04
10000
Equity-to-Asset 0.68
Equity-to-Asset ranked higher than
68.94% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
RVNC: 0.68
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -16.15, Med: 0.86, Max: 0.93
Current: 0.68
-16.15
0.93
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.57
DISTRESS
GREY
SAFE
Beneish M-Score 13.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 4.05%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -3765.80
Operating Margin ranked lower than
93.94% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
RVNC: -3765.8
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -44846.18, Med: -9892.69, Max: -3765.8
Current: -3765.8
-44846.18
-3765.8
Net Margin % -3745.97
Net Margin ranked lower than
93.94% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
RVNC: -3745.97
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -46025.57, Med: -12463.96, Max: -3745.97
Current: -3745.97
-46025.57
-3745.97
ROE % -71.75
ROE ranked lower than
61.88% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
RVNC: -71.75
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -668.62, Med: -54.09, Max: -34.21
Current: -71.75
-668.62
-34.21
ROA % -53.79
ROA ranked lower than
67.62% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
RVNC: -53.79
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -290.83, Med: -56.56, Max: -31.38
Current: -53.79
-290.83
-31.38
ROC (Joel Greenblatt) % -1070.24
ROC (Joel Greenblatt) ranked lower than
61.20% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
RVNC: -1070.24
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1211.29, Med: -377.41, Max: -311.08
Current: -1070.24
-1211.29
-311.08
3-Year Total Revenue Growth Rate 131.60
3-Year Revenue Growth Rate ranked lower than
70.35% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
RVNC: 104.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -50.7, Med: -32, Max: 104.7
Current: 104.7
-50.7
104.7
3-Year Total EBITDA Growth Rate -25.20
3-Year EBITDA Growth Rate ranked lower than
70.70% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
RVNC: -9.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -15.6, Med: -9.7, Max: 9.5
Current: -9.7
-15.6
9.5
3-Year EPS w/o NRI Growth Rate -9.30
3-Year EPS w/o NRI Growth Rate ranked lower than
63.30% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
RVNC: -9.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -9.3, Max: 51.9
Current: -9.3
0
51.9

» RVNC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RVNC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:VKTX TSX:ZYME NAS:MGTA NAS:KURA XAMS:PHARM XKRX:083790 NAS:AXSM SHSE:600866 XKRX:005690 NAS:SRRK NAS:OBSV NAS:FTSV TSX:RVX TSX:AUP ASX:MSB SHSE:603739 SZSE:300381 NAS:ODT XKRX:141080 HKSE:00775
Traded in other countries RTI.Germany
Address 7555 Gateway Boulevard, Newark, CA, USA, 94560
Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The Company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology.

Ratios

Current vs industry vs history
PB Ratio 2.24
PB Ratio ranked lower than
53.53% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
RVNC: 2.24
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.72, Med: 3.84, Max: 8.95
Current: 2.24
1.72
8.95
PS Ratio 114.71
PS Ratio ranked lower than
96.14% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
RVNC: 114.71
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 68.2, Med: 1500, Max: 3972.22
Current: 114.71
68.2
3972.22
EV-to-EBIT -1.81
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
RVNC: -1.81
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -14.1, Med: -5.5, Max: -1.6
Current: -1.81
-14.1
-1.6
EV-to-EBITDA -1.83
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
RVNC: -1.83
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -14.6, Med: -5.6, Max: -1.6
Current: -1.83
-14.6
-1.6
EV-to-Revenue 66.62
EV-to-Revenue ranked lower than
93.39% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
RVNC: 66.62
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 58.8, Med: 927.1, Max: 3230.1
Current: 66.62
58.8
3230.1
Current Ratio 8.13
Current Ratio ranked higher than
72.07% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
RVNC: 8.13
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.05, Med: 9.81, Max: 24.22
Current: 8.13
0.05
24.22
Quick Ratio 8.13
Quick Ratio ranked higher than
72.91% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
RVNC: 8.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.05, Med: 9.81, Max: 24.22
Current: 8.13
0.05
24.22
Days Sales Outstanding 2.00
Days Sales Outstanding ranked lower than
100.00% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
RVNC: 2
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 2, Med: 133.1, Max: 2642.8
Current: 2
2
2642.8

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.30
3-Year Share Buyback Rate ranked higher than
62.89% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
RVNC: -9.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -58, Med: -17.3, Max: -9.3
Current: -9.3
-58
-9.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.24
Price-to-Tangible-Book ranked higher than
54.25% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
RVNC: 2.24
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.8, Med: 4.02, Max: 7.47
Current: 2.24
1.8
7.47
Price-to-Median-PS-Value 0.08
Price-to-Median-PS-Value ranked higher than
70.80% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
RVNC: 0.08
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.02, Med: 0.97, Max: 2.65
Current: 0.08
0.02
2.65
Earnings Yield (Joel Greenblatt) % -55.25
Earnings Yield (Greenblatt) ranked lower than
68.46% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
RVNC: -55.25
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -62.8, Med: -18.3, Max: -7.1
Current: -55.25
-62.8
-7.1

More Statistics

Revenue (TTM) (Mil) $ 3.81
EPS (TTM) $ -3.82
Beta 0.27
Volatility % 21.57
52-Week Range $ 10.51 - 32.45
Shares Outstanding (Mil) 44.01

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y